Nivolumab at home vs. clinic for cancer treatment
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of cancer that is treated with nivolumab alone, like certain melanomas, lung, kidney, or bladder cancers.
- You can travel to the clinic and live within 35 miles or in an area served by the study's home care network.
- You have reliable Wi-Fi at home for remote monitoring.
- You are in good enough health to handle daily activities (ECOG score 0 or 1), with acceptable blood test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.